Pharmaco - Press Releases

Date	Title	Company
31-Mar-2022	Novartis UK response to NICE Appraisal Consultation Document (ACD) for Piqray (alpelisib) for advanced breast cancer patients	Novartis
31-Mar-2022	Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement (news with additional features)	Vivoryon Therapeutics N.V.
31-Mar-2022	Original-Research: M1 Kliniken AG (von First Berlin Equity Research GmbH)	M1 Kliniken AG
31-Mar-2022	Immutep’s efti in combination with MSD’s pembrolizumab shows encouraging antitumor activity in difficult to treat second line metastatic lung cancer patients	Immutep Limited
31-Mar-2022	Fitabeo Therapeutics shortlisted for National StartUp Award	Fitabeo Therapeutics
31-Mar-2022	V-Bio Ventures raises EUR 110 million for its second fund and expands team	V-Bio Ventures
31-Mar-2022	Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines	Sanofi
31-Mar-2022	Pharma Business Development: In-person Format Clearly Beats Video Conferencing	RauCon GmbH & Co. KG
31-Mar-2022	Maruho Deutschland GmbH: Statement of Maruho Deutschland GmbH on the proposed capital measures in the context of the Extraordinary General Meeting on 7 April 2022	Maruho Deutschland GmbH
31-Mar-2022	Turnaround in FY/2021: Significant sales growth (+30%) and substantially improved EBIDTA (+84%) - clear trend towards black zero	aap Implantate AG
31-Mar-2022	Relief Reports Full-Year 2021 Results and Provides Corporate Update	Relief Therapeutics Holding SA
31-Mar-2022	AEVIS VICTORIA SA achieved very strong results on its investments in 2021 with a holding income of CHF 216.4 million and a net profit of CHF 197.6 million	AEVIS VICTORIA SA
30-Mar-2022	MediClin AG: Group sales and Group operating result in the second year of Corona above previous year - cautious outlook for year 2022	MediClin AG
30-Mar-2022	Immutep’s efti in combination with MSD’s pembrolizumab shows encouraging antitumor activity in difficult to treat second line metastatic lung cancer patients	Immutep Limited
30-Mar-2022	SABINA programme demonstrates SABA reliever overuse is a global issue in asthma management	AstraZeneca
30-Mar-2022	EUROPE’S LARGEST COMMERCIAL LAB BUILDING TO BE BUILT AT CANARY WHARF, LONDON, AS FIRST PHASE OF WORLD LEADING HEALTH AND LIFE SCIENCES CLUSTER	Canary Wharf Group
30-Mar-2022	Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease	Scenic Biotech BV
30-Mar-2022	Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic	Invizius Limited
30-Mar-2022	atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform	atai Life Sciences
30-Mar-2022	Availability of the Q1 2022 Memorandum for modelling purposes	Sanofi